Why the study?
Does renal impairment alter the pharmacokinetics and pharmacodynamics of prasugrel compared to healthy subjects?
Population
64 subjects, including those with end-stage renal disease, moderate renal impairment, and matched healthy…
Comparison
Prasugrel single dose or single-dose escalation vs Matched healthy subjects with normal renal…
Design
Other, open-label
Authors
Loading...
Prasugrel maintains platelet inhibition in moderate renal impairment or ESRD despite lower exposure; leaves open dosing and outcome implications.
Does renal impairment alter the pharmacokinetics and pharmacodynamics of prasugrel compared to healthy subjects?
Prasugrel achieves similar platelet inhibition in patients with moderate or end-stage renal disease compared to healthy subjects, despite lower active metabolite exposure in ESRD.
Small et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: